Acute myeloid leukemia transformed to a targetable disease

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) is a common adult cancer with increasing incidence in older populations.
• Traditional treatment involved chemotherapy ('3 + 7' regimen) and stem cell transplantation.
• Recent advancements have introduced targeted therapies for specific AML subtypes.

Purpose of the Study:

• To review the implications of novel molecular targets in AML.
• To elucidate the mechanisms of action for newly approved targeted drugs.
• To discuss pivotal studies supporting the approval of these targeted therapies.

Main Methods:

• Literature review of clinical trials and research studies.
• Analysis of drug mechanisms targeting specific genetic mutations (CD33, FLT3, IDH).
• Discussion of regulatory approval pathways and supporting evidence.

Main Results:

• Several targeted therapies (gemtuzumab ozogamicin, midostaurin, gilteritinib, crenolanib, ivosidenib, enasidenib) are now approved.
• These drugs target specific molecular alterations like CD33 expression, FLT3 mutations, and IDH mutations.
• Targeted therapies have significantly altered the treatment landscape for AML.

Conclusions:

• New targeted agents have transformed AML from a disease with limited options to a treatable condition.
• Understanding specific targets and drug mechanisms is crucial for effective AML management.
• Continued research into targeted therapies promises further improvements in patient outcomes.